Medsource International, LLC – Trademark Portfolio
Entity Type: 16
Medsource International, LLC holds 22 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 18 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 13 trademarks are registered. Notable registered marks include EMERGE, NEUSAFE, VENAPUR, TRUESAFE, and VEROTRUE. The owner is based in Mound, MN.
5346 Shoreline Drive
Mound, MN 55364
Showing of trademarks Trademarks
Trademark Classifications
Medsource International, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Medsource International, LLC have?
Medsource International, LLC has 22 U.S. trademarks filed with the USPTO. Of these, 13 registered, 6 abandoned, 3 cancelled.
What trademark classes does Medsource International, LLC file in?
Medsource International, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Medsource International, LLC's most well-known trademarks?
Medsource International, LLC's registered trademark portfolio includes well-known marks such as EMERGE, NEUSAFE, VENAPUR, TRUESAFE, and VEROTRUE. These are among 13 currently registered trademarks in the portfolio.
What is Medsource International, LLC's trademark registration success rate?
Medsource International, LLC has a 59% trademark registration rate, with 13 out of 22 resolved applications resulting in successful registration. Currently, 0 applications are pending review.